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Thrombocytopenia may be induced by numerous factors,
whereas ciprofloxacin-induced severe thrombocytopenia
rarely occurs [1,2]. Starr et al. [3] reported that a 72-year-old
patient developed thrombocytopenia after ciprofloxacin
treatment for a urinary tract infection. Tuccori et al. [4]
observed abdominal pain, hepatitis, thrombocytopenia, and
hemolysis in a 30-year-old patient after ciprofloxacin treat-
ment for urinary tract infection. In addition to this, Chaudhry
etal. [5] observed that thrombocytopeniaoccurredasa result
of ciprofloxacin treatment for urinary tract infection.
A 61-year-old unconscious patient who was treated at
home for chronic diarrhea for 5 years was admitted to the
emergency room. The patient was given ciprofloxacin
500 mg, twice daily after she did not respond to antipy-
retic treatment. She was also diagnosed with Parkinson’s
disease and was treated with levodopa and baclofen on
regular basis. She was brought to the emergency room
because her health in general was deteriorating. She was
experiencing diarrhea, nausea and vomiting, hypotension,
tachycardia, tachypnea, and fever. When she was diag-
nosed with hypoxemia, she was intubated and taken to
the intensive care unit for mechanical ventilation. Pan-
cultures were obtained and eventually the patient was
placed on intravenous piperacillin-tazobactam 4.5 g. Her
laboratory work-up revealed a white blood cell count of
23,000 per mm3, thrombocyte count of 119,000 per mm3,
and C-reactive protein level of 116 mg/L. Physical ex-
amination revealed decreased lung sounds and crepitant
rales on both lungs.
The patient’s thrombocyte count at 24 hours was
16,000 per mm3. At that time, antiaggregant treatment was
stopped and 12 units of thrombocyte suspension were given
to the patient. The thrombocyte count at 48 hours was
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baclofen treatments were stopped due to their potential
thrombocytopenic effect. The patient’s blood chemistry,
specifically the liver function test, was normal. The com-
plete blood count at 72 hours showed a thrombocyte level
of 36,000 per mm3 and 6 units of thrombocyte solution were
given to the patient.
On the 5th day, levodopa treatment was restarted. The
thrombocyte count was 131,000 per mm3 on the 8th day and
on the following days the count was within normal limits.
Piperacillin-tazobactam was given for 14 days. Our thinking
was that was that the ciprofloxacin treatment given at
home was the cause of the patient’s thrombocytopenia.
Later on the patient had percutaneous tracheostomy and
percutaneous endoscopic gastrostomy and was discharged
home on 30th day of her hospital stay.
The sepsis, disseminated intravascular coagulation,
heparin, levodopa, and ciprofloxacin were considered to
have caused the thrombocytopenia.
In conclusion, our patient developed thrombocytopenia
after receiving ciprofloxacin for 5 days as a treatment for
fever and diarrhea. After our experience, we recommend
that ciprofloxacin be considered one of the causative
agents while evaluating the patient for thrombocyto
penia.
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